METABOLIC BIOMARKER FOR DIAGNOSIS AND TREATMENT OF METASTATIC PROSTATE CANCER

Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

METABOLOMIC PROFILING OF CANCER

The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. 120-. (canceled)21. A method of diagnosing cancer , comprising: a) detecting the presence or level of one or more cancer specific metabolites selected from the group consisting of sarcosine , glutamate , glycine , cysteine , asparagine , leucine , proline , threonine , histidine , n-acetyl-aspartic acid , inosine , inositol , adenosine , taurine , creatine , uric acid , glutathione , uracil , kynurenine , glycerol-s-phosphate , glycocholic acid , suberic acid , xanthosine , 4-acetamidobutyric acid , and thymine in a sample from a subject; and b) diagnosing cancer based on the presence or level of said cancer specific metabolite.22. The method of claim 21 , wherein said cancer is prostate cancer.23. The method of claim 21 , wherein said cancer specific metabolite is present or elevated in cancerous samples but not non-cancerous samples.24. The method of claim 21 , wherein said sample is selected from the group consisting of a tissue sample claim 21 , a blood sample claim 21 , a serum sample claim 21 , and a urine sample.25. The method of claim 24 , wherein said tissue sample is a biopsy sample.26. The method of claim 21 , wherein the sample is analyzed using one or more techniques selected from the group consisting of gas chromatography claim 21 , liquid chromatography claim 21 , mass spectrometry claim 21 , ELISA claim 21 , and antibody linkage.27. The method of claim 21 , wherein said cancer specific metabolite further comprises one or more cancer specific metabolites selected from the group consisting of citrate claim 21 , malate and N-acetyl tyrosine.28. The method of claim 21 , wherein said one or more cancer specific metabolites is two or more markers.29. The method of claim 21 , wherein said one or cancer specific metabolites is three or more markers.30. The method of claim 21 , wherein said one or more ...

Expression profile of prostate cancer

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

Metabolomic profiling of prostate cancer

Expression profile of prostate cancer

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

Expression profile of prostate cancer

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

Prostate cancer expression profile

Un procedimiento para caracterizar tejido de próstata in vitro o ex vivo que comprende: a) proporcionar una muestra de tejido de próstata de un sujeto;b) detectar un nivel de expresión de un marcador en dicha muestra; y c) caracterizar dicha muestra de tejido de próstata, en el que dicho marcador comprende una secuencia de ácidos nucleicos de SEC ID Nº : 95 o un polipéptido codificado por dicha secuencia de ácidos nucleicos, en el que dicha muestra de tejido de próstata se caracteriza como cáncer de próstata cuando dicho nivel de expresión es elevado con respecto a un tejido de próstata no canceroso. A method for characterizing prostate tissue in vitro or ex vivo comprising: a) providing a sample of prostate tissue from a subject; b) detecting a level of expression of a marker in said sample; and c) characterizing said prostate tissue sample, wherein said marker comprises a nucleic acid sequence of SEQ ID NO: 95 or a polypeptide encoded by said nucleic acid sequence, wherein said prostate tissue sample is characterized as prostate cancer when said level of expression is elevated with respect to a non-cancerous prostate tissue.

Expression profile of prostate cancer

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

Protein microarray system

The present invention relates to automated methods, systems, and apparatuses for protein separation and analysis. In particular, the present invention provides an automated system for the separation, identification, and characterization of the phosphorylation status of protein samples, including the generation and analysis of protein microarrays.

Protein microarray system

The present invention relates to automated methods, systems, and apparatuses protein separation and analysis. In particular, the present invention provides an automated system for the separation, identification, and characterization of protein samples. The present invention thus provides improved methods for the separation and analysis of samples containing a plurality of proteins (e.g., cells).

Metabolomic profiling of prostate cancer

The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer.

Protein microarray system

The present invention relates to automated methods, systems, and apparatuses for protein separation and analysis. In particular, the present invention provides an automated system for the separation, identification, and characterization of the phosphorylation status of protein samples, including the generation and analysis of protein microarrays.

Protein microarray system

The present invention relates to automated methods, systems, and apparatuses for protein separation and analysis. In particular, the present invention provides an automated system for the separation, identification, and characterization of protein samples. The present invention thus provides improved methods for the separation and analysis of samples containing a plurality of proteins (e.g., cells).

Protein microarray system

The present invention relates to automated methods, systems, and apparatuses for protein separation and analysis. In particular, the present invention provides an automated system for the separation, identification, and characterization of the phosphorylation status of protein samples, including the generation and analysis of protein microarrays.

Expression profile of prostate cancer

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.

Multiplex metabolic markers in plasma for early detection of african american prostrate cancer

Embodiments of the disclosure include means of identifying and quantifying particular metabolite-based biomarkers for diagnosis and prognosis of prostate cancer in African American men, including at least Methionine, Homocysteine, Glutamic acid, Ornithine, and/or Inosine, and, in some cases, also N-Acetyl Aspartate, Glutamine, Sarcosine, Succinate, and/or Malate.

Multiplex metabolic markers in plasma for early detection of african american prostate cancer

Embodiments of the disclosure include means of identifying and quantifying particular metabolite-based biomarkers for diagnosis and prognosis of prostate cancer in African American men, including at least Methionine, Homocysteine, Glutamic acid, Ornithine, and/or Inosine, and, in some cases, also N-Acetyl Aspartate, Glutamine, Sarcosine, Succinate, and/or Malate.

Expressionsprofil von prostatakarzinom

Verfahren zur bildung eines protein- mikroarraysystems

Multiplex metabolic markers in plasma for early detection of african american prostrate cancer

Embodiments of the disclosure include means of identifying and quantifying particular metabolite-based biomarkers for diagnosis and prognosis of prostate cancer in African American men, including at least Methionine, Homocysteine, Glutamic acid, Ornithine, and/or Inosine, and, in some cases, also N-Acetyl Aspartate, Glutamine, Sarcosine, Succinate, and/or Malate.